> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 3 Approvals Used Priority Review Vouchers
- URL: https://www.fdaweb.com/3-approvals-used-priority-review-vouchers/
- Published: 2018-04-10T12:00:00.000Z
- Updated: 2026-09-14T23:58:20.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141181

*Federal Register* notice: FDA has announced several product approvals that redeemed a priority review voucher. The agency has determined that the following approved drugs met voucher redemption criteria: Sanofi’s Praluent (alirocumab) approved 7/2015; Sanofi’s Soliqua (insulin glargine and lixisenatide) approved 11/2016; and ViiV Healthcare’s Juluca (dolutegravir and rilpivirine) approved 11/2017\. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-04-10/pdf/2018-07256.pdf?ref=fdaweb.com).